L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

Han,Shuwen; Yang,Xi; Pan,Yuefen; Qi,Quan; Shen,Junjun; Fang,Huifen; Ji,Zhaoning

doi:10.3892/ol.2017.6693

L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

Authors:
- Shuwen Han
- Xi Yang
- Yuefen Pan
- Quan Qi
- Junjun Shen
- Huifen Fang
- Zhaoning Ji
View Affiliations

Affiliations: Department of Medical Oncology, Huzhou Central Hospital, Huzhou, Zhejiang 313000, P.R. China, Department of Oncology, Wannan Medical College, Wuhu, Anhui 241000, P.R. China, The Cancer Center, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: August 1, 2017 https://doi.org/10.3892/ol.2017.6693
Pages: 4243-4248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

L-securinine is a natural product extracted and isolated from the leaf of dried Securinega suffruticosa. The aim of the present study was to explore the effects of L‑securinine on proliferation, and the methylation profile of the dickkopf‑related protein 1 (DKK1) gene in human lung cancer cells and fibroblasts. L‑securinine was extracted, isolated and the structure was identified. The cytotoxicity of L‑securinine in A549 cells was evaluated by Cell Counting Kit‑8 assays. The expression and DNA methylation profile of DKK genes was analyzed by reverse transcription‑quantitative polymerase chain reaction and bisulfite sequencing polymerase chain reaction, respectively. L‑securinine inhibited the proliferation of lung cancer cells; the half‑maximal inhibitory concentration values were 8.92, 4.73 and 3.81 µg/ml, at 24, 36 and 48 h post‑treatment, respectively. DKK1, 2 and 3 expression was significantly increased in A549 cells compared with HLF‑a cells. L‑securinine induced the downregulation of DKK1 in A549 cells in a dose‑dependent manner and induced methylation changes at CpG sites in the DKK1 promoter region. L‑securinine may be a potential anticancer drug that mediates its effects by altering DKK1 gene methylation.

View Figures

View References

1	Wood SL, Pernemalm M, Crosbie PA and Whetton AD: Molecular histology of lung cancer: From targets to treatments. Cancer Treat Rev. 41:361–375. 2015. View Article : Google Scholar : PubMed/NCBI
2	Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos, Gil M, Remón J and Rosell R: The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med. 3:12015. View Article : Google Scholar : PubMed/NCBI
3	Li LN, Chen WM and Fang QC: Studies on the extraction and isolation of securinine from securinega suffruticosa (PALL.) REHD by adsorption with active carbon. Yao Xue Xue Bao. 9:352–358. 1962.(In Chinese). PubMed/NCBI
4	Saito S, Kotera K, Shigematsu N, Ide A, Sugimoto N, Horii Z, Hanaoka M, Yamawaki Y and Tamura Y: Structure of securinine. Tetrahedron. 19:2085–2099. 1963. View Article : Google Scholar : PubMed/NCBI
5	Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth BL, Agarwal ML, Tse W, Agarwal MK and Wald DN: Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One. 6:e212032011. View Article : Google Scholar : PubMed/NCBI
6	Treatment of chronic aplastic anemia with securinine-analysis of 123 cases. Zhonghua Nei Ke Za Zhi. 22:764–766. 1983.(In Chinese). PubMed/NCBI
7	Neganova ME, Klochkov SG, Afanasieva SV, Serkova TP, Chudinova ES, Bachurin SO, Reddy VP, Aliev G and Shevtsova EF: Neuroprotective effects of the securinine-analogues: Identification of Allomargaritarine as a lead compound. CNS Neurol Disord Drug Targets. 15:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
8	Beutler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR and Enna SJ: Securinine alkaloids: A new class of GABA receptor antagonist. Brain Res. 330:135–140. 1985. View Article : Google Scholar : PubMed/NCBI
9	Copperman R, Copperman G and Der Marderosian A: From Asia securinine-a central nervous stimulant is used in treatment of amytrophic lateral sclerosis. Pa Med. 76:36–41. 1973.PubMed/NCBI
10	Li M, Han S, Zhang G, Wang Y and Ji Z: Antiproliferative activity and apoptosis-inducing mechanism of L-securinine on human breast cancer MCF-7 cells. Pharmazie. 69:217–223. 2014.PubMed/NCBI
11	Han S, Zhang G, Li M, Chen D, Wang Y, Ye W and Ji Z: L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 31:2245–2251. 2014.PubMed/NCBI
12	Choi HJ, Park H, Lee HW and Kwon YG: The Wnt pathway and the roles for its antagonists, DKKS, in angiogenesis. IUBMB Life. 64:724–731. 2012. View Article : Google Scholar : PubMed/NCBI
13	Abdel-Magid AF: Wnt/β-catenin signaling pathway inhibitors: A promising cancer therapy. ACS Med Chem Lett. 5:956–957. 2014. View Article : Google Scholar : PubMed/NCBI
14	Xue G, Romano E, Massi D and Mandalà M: Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treat Rev. 49:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chandra V and Hong KM: Effects of deranged metabolism on epigenetic changes in cancer. Arch Pharm Res. 38:321–337. 2015. View Article : Google Scholar : PubMed/NCBI
16	Walter K, Holcomb T, Januario T, Yauch RL, Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GMS and Shames D: Discovery and development of DNA methylation-based biomarkers for lung cancer. Epigenomics. 6:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ko M, An J, Pastor WA, Koralov SB, Rajewsky K and Rao A: TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev. 263:6–21. 2015. View Article : Google Scholar : PubMed/NCBI
18	Carless MA: Investigation of genomic methylation status using methylation-specific and bisulfite sequencing polymerase chain reaction. Methods Mol Biol. 1288:193–212. 2015. View Article : Google Scholar : PubMed/NCBI
19	Jiang M, Zhang Y, Fei J, Chang X, Fan W, Qian X, Zhang T and Lu D: Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest. 90:282–290. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hughes S and Jones JL: The use of multiple displacement amplified DNA as a control for methylation specific PCR, pyrosequencing, bisulfite sequencing and methylation-sensitive restriction enzyme PCR. BMC Mol Biol. 8:912007. View Article : Google Scholar : PubMed/NCBI
21	Reed K, Poulin ML, Yan L and Parissenti AM: Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation. Anal Biochem. 397:96–106. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chirkin E, Atkatlian W, Do Q, Gaslonde T, Dufat TH, Michel S, Lemoine P, Genta-Jouve G and Porée FH: Chiroptical study and absolute configuration of securinine oxidation products. Nat Prod Res. 29:1235–1242. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wang Xiao, Ming Zheng and Hong Yan: The extraction technology of securinine. Agricultural Food Products Science and Technology. 5:6–1112. 2011.
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Navanesan S, Wahab Abdul N, Manickam S and Sim KS: Leptospermum flavescens constituent-LF1 causes cell death through the induction of cell cycle arrest and apoptosis in human lung carcinoma cells. PLoS One. 10:e01359952015. View Article : Google Scholar : PubMed/NCBI
26	Sood S and Srinivasan R: Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines. Mol Cell Biochem. 404:181–191. 2015. View Article : Google Scholar : PubMed/NCBI
27	Nardi-Agmon I and Peled N: Exhaled breath analysis for the early detection of lung cancer: Recent developments and future prospects. Lung Cancer (Auckl). 8:31–38. 2017.PubMed/NCBI
28	Chen Z, Mei J, Liu L, Wang G, Li Z, Hou J, Zhang Q, You Z and Zhang L: PD-L1 expression is associated with advanced non-small cell lung cancer. Oncol Lett. 12:921–927. 2016.PubMed/NCBI
29	Ge L and Shi R: Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med. 8:10330–10339. 2015.PubMed/NCBI
30	Atherly AJ and Camidge DR: The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 106:1100–1106. 2012. View Article : Google Scholar : PubMed/NCBI
31	Lantermann AB, Chen D, McCutcheon K, Hoffman G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G, Stegmeier F, et al: Inhibition of casein kinase 1 alpha prevents acquired drug resistance to erlotinib in EGFR-mutant non-small celllung cancer. Cancer Res. 75:4937–4948. 2015. View Article : Google Scholar : PubMed/NCBI
32	Yang X, Han SW, Liu H, Zhu L, Chen YX and Ji ZN: Secreted frizzled-related protein 1 (SFRP1) gene methylation changes in the human lung adenocarcinoma cells treated with L-securinine. J Asian Nat Prod Res. 1–19. 2017. View Article : Google Scholar
33	Gills JJ, Granville CA and Dennis PA: Targeting aberrant signal transduction pathways in lung cancer. Cancer Biol Ther. 3:147–155. 2004. View Article : Google Scholar : PubMed/NCBI
34	Jiang XT, Ma YY, Guo K, Xia YJ, Wang HJ, Li L, He XJ, Huang DS and Tao HQ: Assessing the diagnostic value of serum Dickkopf-related protein 1 levels in cancer detection: A case-control study and meta-analysis. Asian Pac J Cancer Prev. 15:9077–9083. 2014. View Article : Google Scholar : PubMed/NCBI
35	Tian J, Xu XJ, Shen L, Yang YP, Zhu R, Shuai B, Zhu XW, Li CG, Ma C and Lv L: Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis. J Huazhong Univ Sci Technolog Med Sci. 35:212–218. 2015. View Article : Google Scholar : PubMed/NCBI
36	Sonohara F, Inokawa Y, Hayashi M, Kodera Y and Nomoto S: Epigenetic modulation associated with carcinogenesis and prognosis of human gastric cancer. Oncol Lett. 13:3363–3368. 2017.PubMed/NCBI
37	Shinjo K and Kondo Y: Targeting cancer epigenetics: Linking basic biology to clinical medicine. Adv Drug Deliv Rev. 95:56–64. 2015. View Article : Google Scholar : PubMed/NCBI